TET1 Isoforms Have Distinct Expression Pattern, Localization and Regulation in Breast Cancer.

TET1 breast cancer demethylation isoforms methylation

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2022
Historique:
received: 04 01 2022
accepted: 08 04 2022
entrez: 1 6 2022
pubmed: 2 6 2022
medline: 2 6 2022
Statut: epublish

Résumé

TET1 regulates gene expression by demethylating their regulatory sequences through the conversion of 5-methylcytosine to 5-hyroxymethylcytosine. TET1 plays important roles in tissue homeostasis. In breast cancer, TET1 was shown to play controversial roles. Moreover, TET1 has at least two isoforms (long and short) that have distinct expression pattern and apparently different functions in tissue development and disease including breast cancer. We hypothesized that TET1 isoforms have different expression patterns, localization and regulation in different types of breast cancer. To prove our hypothesis, we studied the expression of TET1 isoforms in basal and luminal breast cancer cell lines, as well as in basal and luminal breast cancer animal models. We also studied the effect of different hormones on the expression of the two isoforms. Moreover, we assessed the distribution of the isoforms between the cytoplasm and nucleus. Finally, we overexpressed the full length in a breast cancer cell line and tested its effect on cancer cell behavior. In this study, we demonstrate that while Estrogen and GnRH downregulate the expression of long TET1, they lead to upregulation of short TET1 expression. In addition, we uncovered that luminal cells show higher expression level of the long isoform. We also show that while all TET1 isoforms are almost depleted in a basal breast cancer animal model, the expression of the short isoform is induced in luminal breast cancer model. The short form is expressed mainly in the cytoplasm while the long isoform is expressed mainly in the nucleus. Finally, we show that long TET1 overexpression suppresses cell oncogenic phenotypes. In conclusion, our data suggest that TET1 isoforms have distinct expression pattern, localization and regulation in breast cancer and that long TET1 suppresses oncogenic phenotypes, and that further studies are necessary to elucidate the functional roles of different TET1 isoforms in breast cancer.

Identifiants

pubmed: 35646706
doi: 10.3389/fonc.2022.848544
pmc: PMC9133332
doi:

Types de publication

Journal Article

Langues

eng

Pagination

848544

Informations de copyright

Copyright © 2022 Alzahayqa, Jamous, Khatib and Salah.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Biochim Biophys Acta. 2016 Nov;1862(11):2177-2185
pubmed: 27555295
Oncogene. 2015 Aug 6;34(32):4168-76
pubmed: 25362856
Medicine (Baltimore). 2020 Oct 30;99(44):e22863
pubmed: 33126331
Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):10131-10136
pubmed: 28855337
Cancer Res. 2016 May 15;76(10):3097-108
pubmed: 27197233
Oncol Lett. 2018 Jan;15(1):278-284
pubmed: 29285192
Science. 2009 May 15;324(5929):930-5
pubmed: 19372391
Trends Cancer. 2021 Jul;7(7):635-646
pubmed: 33468438
Oncol Lett. 2017 May;13(5):3921-3927
pubmed: 28521490
PLoS One. 2015 Jul 24;10(7):e0133896
pubmed: 26207381
Sci Adv. 2018 Jun 20;4(6):eaap7309
pubmed: 29938218
Mol Oncol. 2011 Feb;5(1):5-23
pubmed: 21147047
Nat Rev Cancer. 2011 Sep 23;11(10):726-34
pubmed: 21941284
Pharmaceuticals (Basel). 2021 Jun 29;14(7):
pubmed: 34209564
Oncogene. 2015 Oct 16;34(42):5309-16
pubmed: 25703331
Cell. 2012 Jul 6;150(1):12-27
pubmed: 22770212
Cancer Res. 2007 Oct 15;67(20):9835-43
pubmed: 17942914
Breast Cancer Res Treat. 2015 Aug;153(1):219-34
pubmed: 26253945
Mol Cell. 2016 Dec 15;64(6):1062-1073
pubmed: 27916660
Sci Rep. 2016 May 26;6:26591
pubmed: 27225590
Mol Cancer Res. 2020 Dec;18(12):1803-1814
pubmed: 32913111
Nat Genet. 2009 Feb;41(2):178-186
pubmed: 19151715
Oncogene. 2013 Jan 31;32(5):663-9
pubmed: 22391558
Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9920-5
pubmed: 23716660
Blood. 2011 Oct 27;118(17):4509-18
pubmed: 21803851
Reproduction. 2020 Aug;160(2):247-257
pubmed: 32422604
Nat Commun. 2015 Nov 26;6:10071
pubmed: 26607761
Cancer Res. 2018 Aug 1;78(15):4126-4137
pubmed: 29891505
Cell Rep. 2012 Sep 27;2(3):568-79
pubmed: 22999938
Cancer Res. 2015 Sep 15;75(18):3912-24
pubmed: 26294212
Theranostics. 2019 Jan 24;9(3):761-777
pubmed: 30809307
Annu Rev Biochem. 2012;81:97-117
pubmed: 22404632
Nucleic Acids Res. 2012 Jun;40(11):4841-9
pubmed: 22362737
Genes Dev. 2016 Apr 1;30(7):733-50
pubmed: 27036965
Nucleic Acids Res. 2017 Aug 21;45(14):8269-8281
pubmed: 28531272
Genome Biol. 2018 Dec 11;19(1):218
pubmed: 30537986
Genome Med. 2015 Jan 29;7(1):9
pubmed: 25632305
Development. 2012 Jun;139(11):1895-902
pubmed: 22569552

Auteurs

Mahmoud Alzahayqa (M)

Molecular Genetics Lab, Medicare Laboratories, Ramallah, Palestine.

Abrar Jamous (A)

Department of Molecular Biology and Biochemistry, Al Quds University, Jerusalem, Palestine.

Areej A H Khatib (AAH)

Women Health Research Unit, McGill University Health Center, Montreal, QC, Canada.

Zaidoun Salah (Z)

Molecular Genetics and Genetic Toxicology Program, Arab American University, Ramallah, Palestine.

Classifications MeSH